Multiple Myeloma

Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date February 21, 2020

In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.

Mass Spectrometry for Detection of Monoclonal Gammopathy of Undetermined Significance

By

Vicki Moore, PhD

Publish Date January 29, 2020

Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.

Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma

By

John Schieszer, MA

Publish Date January 27, 2020

Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.

MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date January 15, 2020

Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.

Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early

By

Susan Moench, PhD, PA-C

Publish Date January 13, 2020

Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.